NASDAQ · HSCSW
Healthcare · Medical - Devices
$0.07
Up+$0.01 (+18.40%)
Updated Sep 12, 2026, 4:08 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 10 trading sessions · Daily adjusted prices
HSCSW closed at $0.07 after 10 trading sessions, up 54.76% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.0695 | $0.0698 | $0.065 | $0.065 | 7.7K |
| Sep 10, 2026 | $0.057 | $0.0571 | $0.0525 | $0.0549 | 5.2K |
| Sep 9, 2026 | $0.0797 | $0.08 | $0.0703 | $0.0799 | 14.26K |
| Sep 8, 2026 | $0.0797 | $0.0898 | $0.0797 | $0.0856 | 44.64K |
| Sep 4, 2026 | $0.0652 | $0.0652 | $0.0652 | $0.0652 | 5.11K |
| Sep 2, 2026 | $0.0501 | $0.0583 | $0.045 | $0.045 | 6.75K |
| Aug 27, 2026 | $0.0565 | $0.0565 | $0.0403 | $0.0403 | 5.09K |
| Aug 26, 2026 | $0.05 | $0.0502 | $0.05 | $0.0502 | 752 |
| Aug 25, 2026 | $0.05 | $0.05 | $0.0441 | $0.0441 | 608 |
| Aug 20, 2026 | $0.0701 | $0.0701 | $0.042 | $0.042 | 10.09K |
The latest Smart Investors Daily articles mentioning HSCSW.
HSCSW research
Company profile and research snapshot.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 15, 2025
HeartSciences Inc. will host an Investor Webinar and present at the Emerging Growth Conference 85 on August 20, 2025, to provide updates on their AI-powered medical technology for ECG/EKG analysis.
GlobeNewswire Inc. · May 29, 2025
HeartSciences, an AI-powered medical technology company, announced its first commercial customer for the MyoVista Insights platform, Westcliffe Health Innovations in the U.K. This partnership aims to enhance ECG management and improve healthcare efficiency.
GlobeNewswire Inc. · May 1, 2025
HeartSciences, an AI-powered medical technology company, has launched the MyoVista Insights platform, a cloud-native ECG management system designed to enhance clinical decision-making and healthcare IT efficiency. The platform features AI-ECG algorithms, streamlined workflows, and advanced cybersecurity.
GlobeNewswire Inc. · Jun 4, 2024
Southlake, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that on June 3, 2024, the Company received formal notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC indicating that HeartSciences has regained compliance with bid price requirement as set forth in Listing Rule 5550(a)(2), and that the Company is therefore in compliance with the Nasdaq Capital Market’s listing requirements and the scheduled hearing has now been cancelled.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HSCSW.
No results
No recent SID articles mention HSCSW.
